SynenTec to Take Over Roche Cellavista System
PENZBERG, Germany, July 31, 2012 /PRNewswire/ --
Roche and SynenTec today announced that Roche will transfer its Cellavista business to SynenTec, the German company which is the original inventor of the Cellavista System. This agreement was made as a result of the Roche Applied Science decision to focus its business, and guarantees future optimal support and development of the technology for its customers.
The Cellavista Imaging System for noninvasively measuring cell expansion uses brightfield and fluorescence detection with multiwell plates, chamber slides or RoboFlasks, for a broad range of cellular applications in cell line development, cellular research and drug discovery.
"It is very important that we ensure uninterrupted support for our customers. We have found the ideal match in SynenTec", said Dan Zabrowski, Head of Roche Applied Science.
"This acquisition adds significant value for Cellavista customers by enabling them to directly discuss their requirements and needs with the developer of the system," says Matthias Pirsch, CEO of SynenTec.
Over the last years, SynenTec collaborated with Roche in cell imaging, and was closely involved in the development, service and support of Cellavista Systems. With the business transfer SynenTec will take on worldwide distribution of Cellavista Systems, as well as providing application support and service. Roche will remain the primary contact partner for all support needs for Cellavista Systems delivered by Roche or Innovatis over a transition phase until SynenTec assumes full responsibility on June 01, 2013.
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2011, Roche had over 80,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 42.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: http://www.roche.com.
For life science research only. Not for use in diagnostic procedures.
CELLAVISTA and INNOVATIS are trademarks of Roche.
All other product names and trademarks are the property of their respective owners.
For further information please contact:
Dr. Burkhard Ziebolz
SOURCE Roche Diagnostics